ProQR Therapeutics (NASDAQ:PRQR) Director Acquires $231,000.00 in Stock

ProQR Therapeutics N.V. (NASDAQ:PRQR) Director Bart Filius purchased 150,000 shares of the stock in a transaction that occurred on Friday, June 26th. The stock was purchased at an average cost of $1.54 per share, with a total value of $231,000.00. Following the purchase, the director owned 150,000 shares in the company, valued at $231,000. This represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

ProQR Therapeutics Price Performance

NASDAQ:PRQR traded up $0.03 during mid-day trading on Tuesday, reaching $1.86. The stock had a trading volume of 1,032,128 shares, compared to its average volume of 654,152. The stock has a market cap of $195.97 million, a P/E ratio of -3.72 and a beta of 0.07. The business’s 50 day moving average is $1.60 and its 200 day moving average is $1.71. ProQR Therapeutics N.V. has a fifty-two week low of $1.33 and a fifty-two week high of $3.10.

ProQR Therapeutics (NASDAQ:PRQR) last posted its earnings results on Tuesday, May 12th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.15). The firm had revenue of $2.35 million during the quarter, compared to analysts’ expectations of $5.19 million. ProQR Therapeutics had a negative net margin of 331.33% and a negative return on equity of 84.87%. Equities analysts expect that ProQR Therapeutics N.V. will post -0.57 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on PRQR shares. JonesTrading decreased their price objective on shares of ProQR Therapeutics from $11.00 to $10.00 and set a “buy” rating for the company in a report on Friday. Citigroup reaffirmed a “market outperform” rating on shares of ProQR Therapeutics in a research report on Wednesday, May 27th. Oppenheimer initiated coverage on ProQR Therapeutics in a report on Thursday, March 12th. They set an “outperform” rating and a $9.00 price objective on the stock. Weiss Ratings downgraded ProQR Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 23rd. Finally, Wall Street Zen lowered ProQR Therapeutics from a “hold” rating to a “strong sell” rating in a report on Saturday, May 16th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, ProQR Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $7.33.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Osaic Holdings Inc. boosted its holdings in ProQR Therapeutics by 59.6% during the second quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 4,500 shares during the period. Guggenheim Capital LLC bought a new position in shares of ProQR Therapeutics in the fourth quarter worth about $35,000. Moody Lynn & Lieberson LLC bought a new position in shares of ProQR Therapeutics in the fourth quarter worth about $50,000. Invesco Ltd. acquired a new position in shares of ProQR Therapeutics during the 4th quarter worth about $51,000. Finally, Axiom Investment Management LLC bought a new stake in ProQR Therapeutics during the 1st quarter valued at approximately $53,000. Institutional investors and hedge funds own 32.65% of the company’s stock.

About ProQR Therapeutics

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.